AnaptysBio
ANAB
121 hedge funds and large institutions have $460M invested in AnaptysBio in 2019 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 47 increasing their positions, 19 reducing their positions, and 38 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
147% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 19
2% more funds holding
Funds holding: 119 → 121 (+2)
5% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 38
3.13% less ownership
Funds ownership: 107.36% → 104.23% (-3.1%)
32% less call options, than puts
Call options by funds: $7.83M | Put options by funds: $11.5M
55% less capital invested
Capital invested by funds: $1.02B → $460M (-$557M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$46.5M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$43.6M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$30.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$24.9M |
| 5 |
PA
Perceptive Advisors
New York
|
+$23.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$94.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$91.8M |
| 3 |
Janus Henderson Group
London,
|
-$87.6M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$42.3M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$30.2M |
ANAB Hedge Fund Activity: Q4 2019 in Review
121 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q4 2019, worth a combined $460M — down 55% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new ANAB positions and 38 closed out — a net gain of 2 holders — while 47 added to existing stakes and 19 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $46.5M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $94.3M sold.
- 121 institutional investors held AnaptysBio (ANAB) as of Q4 2019, up from 119 in Q3 2019.
- Funds reported $460M of AnaptysBio stock for Q4 2019, down 55% quarter-over-quarter.
- 40 funds opened new AnaptysBio positions in Q4 2019 and 38 closed out, a net change of +2 holders.
- The largest AnaptysBio buyer in Q4 2019 was EcoR1 Capital, an estimated $46.5M added.
- The largest AnaptysBio seller in Q4 2019 was Adage Capital Partners, an estimated $94.3M sold.
Based on aggregated 13F filings for Q4 2019.